Company profile: Viventia Bio
1.1 - Company Overview
Company description
- Provider of next-generation oncology therapeutics utilizing proprietary Targeted Protein Therapeutic (TPT) technology; a privately held biopharmaceutical company focused on the discovery and development of TPT-based product candidates with potential advantages in treating cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Viventia Bio
CASI Pharmaceuticals
HQ: United States
Website
- Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CASI Pharmaceuticals company profile →
Apollomics
HQ: United States
Website
- Description: Provider of oncology biopharmaceuticals discovering and developing mono- and combination therapies to harness the immune system. Pipeline: APL-502 (PD-L1 mAb) and APL-501 (PD-1 mAb) outside mainland China; EO1001/APL-122 (small molecule) for development outside mainland China, Hong Kong and Taiwan; uproleselan/APL-106 and GMI-1687/APL-108 (E-selectin antagonists) in mainland China, Hong Kong, Macau and Taiwan; TYG100/APL-810 in Greater China and South Africa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apollomics company profile →
Quanticel
HQ: United States
Website
- Description: Provider of oncology drug discovery, leveraging a proprietary single-cell genomic analysis platform for human cancer to enable the discovery and development of breakthrough, first-in-class cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanticel company profile →
Sareum
HQ: United Kingdom
Website
- Description: Provider of targeted small molecule therapeutics for cancer and autoimmune diseases, delivering drug candidates for licensing at pre-clinical or early clinical stages. Pipeline includes SDC-1801 and SDC-1802 (TYK2/JAK1 inhibitors) and SRA737 (clinical-stage, oral, selective Chk1 inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sareum company profile →
Cellestia
HQ: Switzerland
Website
- Description: Provider of clinical-stage R&D therapies to control and modulate pathogenic gene expression via selective inhibition of transcription factors in the cell nucleus. Lead candidate CB-103 targets the CSL-NOTCH complex and is in Phase 2 for various cancers and GvHD, showing efficacy in multi-drug resistant cancers and autoimmune diseases. Pipeline includes preclinical assets for psoriasis, Sjogren’s, SLE, IBD and giant cell arteritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Viventia Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Viventia Bio
2.2 - Growth funds investing in similar companies to Viventia Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Viventia Bio
4.2 - Public trading comparable groups for Viventia Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →